Premium
A randomised, double‐blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life
Author(s) -
Voss Simon,
Quail Deborah,
Dawson Alison,
Bäckström Tjorbörn,
Aguas Fernanda,
Erenus Mithat,
The Hok Sien,
Bonnar John,
Geyter Christian,
Hunter Myra,
Nickelsen Thomas
Publication year - 2002
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2002.01510.x
Subject(s) - medicine , discontinuation , raloxifene , quality of life (healthcare) , adverse effect , hormone replacement therapy (female to male) , population , visual analogue scale , physical therapy , obstetrics , gynecology , tamoxifen , breast cancer , nursing , environmental health , cancer , testosterone (patch)
Objective To compare continuous combined hormone replacement therapy (ccHRT) and raloxifene with respect to compliance and quality of life, which were predefined secondary endpoints of a large, prospective study designed to investigate the uterine effects of both treatments. Design Double‐blind, randomised controlled trial of six‐month duration. Setting One hundred and twenty‐nine gynaecology hospital departments, clinics or practices specialised in women's healthcare, located in Europe, South Africa and Israel. Population Healthy postmenopausal women ( n = 1008 ). Main outcome measures Changes in quality of life using the Women's Health Questionnaire (WHQ) and compliance using a compliance questionnaire and pill count. Adverse event and early discontinuation rates and satisfaction with treatment using a visual analogue scale (VAS). Results Women taking raloxifene reported greater satisfaction with their treatment as assessed on the VAS ( P = 0.004 ),and a lower proportion, as compared with ccHRT, reported being worried by the treatment ( 9.6% vs 20.2%, P < 0.01 ). Women taking ccHRT reported greater deterioration in scores from the WHQ for depressed mood and menstrual symptoms than those taking raloxifene ( P < 0.01 ). For memory, vasomotor symptoms and sexual behaviour, the ccHRT group reported significantly greater mean improvements ( P < 0.05 ). Over half (58.8%) of those taking raloxifene noticed no effect, 37.7% felt better and 3.4% felt worse as measured using the compliance questionnaire. Fifty percent of the women taking ccHRT felt better, 37.8% noticed no effect but over 10% felt worse. More women on raloxifene (94.6%) than on ccHRT (85.9%) reported that they were taking their double‐blinded medication regularly ( P < 0.01 ). Conclusions A lower rate of adverse event‐related discontinuations, the lack of negative effects on quality of life and a smaller proportion of women being worried by the drug treatment were associated with higher treatment satisfaction and better compliance in postmenopausal women taking ccHRT or raloxifene.